Clinical Trials Logo

Lymphocytic Lymphoma clinical trials

View clinical trials related to Lymphocytic Lymphoma.

Filter by:
  • None
  • Page 1

NCT ID: NCT05260203 Completed - Multiple Myeloma Clinical Trials

MargheRITA (Remote Intelligence for Therapeutic Adherence)

MargheRITA
Start date: June 4, 2022
Phase: N/A
Study type: Interventional

It is essential to improve clinical efficiency and management of hematological and oncological patients treated on an outpatient basis. The most promising operative way to achieve this result is the development of tele-oncology platforms, that allow not only a telemedicine visit, but also the patient support in the daily management of the disease and related disorders, as well as treatments and their complications. In this perspective, the RITA communication platform should be able to support the patient, the caregiver, the physician and the general practitioner in the management of the disease and its treatments.

NCT ID: NCT01849939 Recruiting - Clinical trials for Chronic Lymphocytic Leukemia

Eradication of Residual Disease by Preemptive Immunointervention After Allogeneic Hematopoietic Stem Cells Transplantation in Chronic Lymphocytic Leukemia

RICAC
Start date: September 2012
Phase: Phase 2
Study type: Interventional

Usually Chronic lymphocytic leukemia (CLL) is a disease of the elderly patients. However, the diagnosis in young patients become more frequently with poor prognosis. The identification of new prognostic factors permits early determination of the high risk population and provide them the therapeutic intensification. Allogeneic transplantation of hematopoietic stem cells transplantation (AHSCT) allows to long-term remission and in some cases complete and definitive eradication of the disease. After chemotherapy or antibodies, the Minimal Residual Disease (MRD) negativity is associated with better disease-free survival. MRD negativity occurs in some patients with the appearance of GVHD, stopping the immunosuppression or after donor lymphocyte injection (DLI). The negativity of MRD in the first year post-transplant is correlated with better progression-free survival or overall survival (Dreger 2010, Farina 2009, Caballero 2005, Algrin, 2011). So, MRD negativity may be an objective after AHSCT. The aim of this prospective study is to evaluate a standardized preemptive immunointervention of post-allograft immunosuppressive therapy modulation and DLI administration according to MRD level. The objective is to obtain MRD negativity at 12 months after AHSCT.

NCT ID: NCT00877214 Active, not recruiting - Clinical trials for Non-Hodgkin's Lymphoma

Significance of Duration of Maintenance Therapy With Rituximab in Non-Hodgkin Lymphomas

MAINTAIN
Start date: April 1, 2009
Phase: Phase 3
Study type: Interventional

The purpose of this study is to determine if an extended maintenance therapy with Rituximab in follicular and a maintenance therapy in other indolent and mantle cell lymphomas has advantages compared to a shorter or no maintenance therapy.